Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cell Therapy in Recurrent Ovarian Cancer
NCT06321484Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cytokine-induced memory-like natural killer cells in ovarian cancer (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 60 days and Dose Limiting Toxicity at 60 days. Started Oct 2024; status: recruiting.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06321484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321484.